Floatz logo

EXEMESTANE

Chronic Low Back Pain

VA Office of Research and DevelopmentSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Chronic Low Back Pain cohort.

Asset / SponsorPhaseRating
DICLOFENAC
Organon and Co
Phase 4BB
Etoricoxib
Organon and Co
Phase 4BB
Sra-333
Wake Forest University
Phase 4B
Tapentadol
Janssen Scientific Affairs, LLC
Phase 4B
Dfn-15
Endo USA Inc., a Keenova Therapeutics Company
Phase 4B

View all 15 →

Same molecule, other indications

EXEMESTANE is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
ER+ Breast CancerDormant
BBB
Indicative ·
75 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →